Comparison of inhaled corticosteroids

OBJECTIVE: To review the comparative studies evaluating both efficacy and safety of inhaled corticosteroids in the management of asthma. Specifically, comparative clinical trials are evaluated that allow clinicians to determine relative potencies of the various inhaled corticosteroids. METHODS: A critical review was performed of the published clinical trials, either as articles or abstracts, comparing the clinical efficacy or systemic activity of inhaled corticosteroids. No a priori criteria were applied, as this was not a meta-analysis. FINDINGS: In vitro measures of antiinflammatory activity of corticosteroids consistently demonstrate potency differences among the various corticosteroids. Traditionally, these in vitro measures have been used to develop new corticosteroids with greater topical activity. While no accepted direct measure of antiasthmatic antiinflammatory activity exists, clinical trials using surrogate measures (e.g., forced expiratory volume in 1 second, peak expiratory flow, bronchial hyperresponsiveness, symptom control) indicate that in vitro measures provide a relatively accurate assessment of antiasthmatic potency. The relative antiinflammatory potency of the inhaled corticosteroids is in the following rank order. flunisolide = triamcinolone acetonide < beclomethasone dipropionate = budesonide < fluticasone. Studies of systemic activity appear to confirm this relative order of potency. Currently, no evidence exists for greater efficacy for any of the inhaled corticosteroids when administered in their relative equipotent dosages. The preponderance of current data suggests that when administered in equipotent antiinflammatory doses as a metered-dose inhaler plus spacer or as their respective dry-powder inhaler, the existing inhaled corticosteroids have similar risks of producing systemic effects. CONCLUSIONS: Delivery systems can significantly affect both topical and systemic activity of inhaled corticosteroids. More direct comparative studies between agents are required to firmly establish comparative topical to systemic activity ratios. The preponderance of evidence suggests that the agents are not equipotent on a microgram basis.

This article has been cited by other articles:

				H W. Kelly Comparison of Inhaled Corticosteroids: An Update Ann. Pharmacother., March 1, 2009; 43(3): 519 - 527. [Abstract] [Full Text] [PDF]

				T. Parimon, J. W. Chien, C. L. Bryson, M. B. McDonell, E. M. Udris, and D. H. Au Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 712 - 719. [Abstract] [Full Text] [PDF]

				Q. Zhao, E. G. Shepherd, M. E. Manson, L. D. Nelin, A. Sorokin, and Y. Liu The Role of Mitogen-activated Protein Kinase Phosphatase-1 in the Response of Alveolar Macrophages to Lipopolysaccharide: ATTENUATION OF PROINFLAMMATORY CYTOKINE BIOSYNTHESIS VIA FEEDBACK CONTROL OF p38 J. Biol. Chem., March 4, 2005; 280(9): 8101 - 8108. [Abstract] [Full Text] [PDF]

				T. A. Lee and K. B. Weiss Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 855 - 859. [Abstract] [Full Text] [PDF]

				E.S. Mendes, A. Pereira, I. Danta, R.C. Duncan, and A. Wanner Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids Eur. Respir. J., June 1, 2003; 21(6): 989 - 993. [Abstract] [Full Text] [PDF]

				K. G. Lim Management of Persistent Symptoms in Patients With Asthma Mayo Clin. Proc., December 1, 2002; 77(12): 1333 - 1339. [Abstract] [PDF]

				R. Blais, J.-P. Gregoire, R. Rouleau, A. Cartier, J. Bouchard, and L.-P. Boulet Ambulatory Use of Inhaled {beta}2-Agonists for the Treatment of Asthma in Quebec : A Population-Based Utilization Review Chest, May 1, 2001; 119(5): 1316 - 1321. [Abstract] [Full Text] [PDF]

				The use of inhaled corticosteroids in adults with asthma DTB, January 1, 2000; 38(1): 5 - 8. [Abstract] [Full Text] [PDF]